About
Elizabeth A. Garofalo, M.D., has served as an ACADIA director since September 2020. Since 2016 she has been Principal of EAG Pharma Consulting, and she previously held senior leadership roles at Novartis, including Senior Vice President and Global Head of Clinical Development, and served as head of the neuroscience therapy area at Astellas Pharma. She currently serves on the boards of Alector and Xenon Pharmaceuticals. She earned her M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan.
Roles
Acadia Pharmaceuticals Inc.
Director · Current role
September 2020–present
EAG Pharma Consulting LLC
Principal
2016 - present
Novartis International AG
Senior Vice President and Global Head of Clinical Development
—
Astellas Pharma, Inc.
Vice President and Head, Neuroscience Therapy Area
—
Parke-Davis / Pfizer
Site Head of Neuroscience and Worldwide Regulatory Affairs (Ann Arbor)
—
External Roles
Alector, Inc.
Director
—
Xenon Pharmaceuticals Inc.
Director
—
Director Compensation
FY 2025Fees earned or paid in cash
$35,575
ComponentAnnual Board and committee cash retainers earned in FY2025
Option awards
$176,392
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$180,705
ComponentAnnual restricted stock unit grant, ASC 718 grant-date fair value
Total
$392,671
Also at Acadia Pharmaceuticals Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.